These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33971041)

  • 1. Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
    Hall KH; Brooks A; Waller EK
    Am J Hematol; 2021 Aug; 96(8):E293-E295. PubMed ID: 33971041
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of bosutinib in the treatment of chronic myeloid leukemia.
    Gambacorti-Passerini C; le Coutre P; Piazza R
    Future Oncol; 2020 Jan; 16(2):4395-4408. PubMed ID: 31833784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
    Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
    Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asciminib as a new option in the treatment of chronic myeloid leukemia.
    İbiş B; Tiribelli M; Eşkazan AE
    Future Oncol; 2021 Dec; 17(36):5003-5005. PubMed ID: 34791894
    [No Abstract]   [Full Text] [Related]  

  • 5. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
    Hill BG; Kota VK; Khoury HJ
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosutinib in the treatment of chronic myelogenous leukemia.
    Cortes J
    Clin Adv Hematol Oncol; 2012 Nov; 10(11):736-7. PubMed ID: 23271260
    [No Abstract]   [Full Text] [Related]  

  • 7. Bosutinib for the treatment of chronic myeloid leukemia.
    Doan V; Wang A; Prescott H
    Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Syed YY; McCormack PL; Plosker GL
    BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach.
    García Molina A
    Farm Hosp; 2024; 48(5):T222-T229. PubMed ID: 39013681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach.
    Garcia Molina A
    Farm Hosp; 2024; 48(5):222-229. PubMed ID: 38679535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosutinib.
    Keller G; Schafhausen P; Brümmendorf TH
    Recent Results Cancer Res; 2010; 184():119-27. PubMed ID: 20072835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.
    Minami Y; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Dawson MK; Matsumura I
    Int J Hematol; 2024 Sep; 120(3):305-313. PubMed ID: 38888812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia.
    Jain N; Maiti A; Ravandi F; Konopleva M; Daver N; Kadia T; Pemmaraju N; Short N; Kebriaei P; Ning J; Cortes J; Jabbour E; Kantarjian H
    Am J Hematol; 2021 Aug; 96(8):1000-1007. PubMed ID: 33991360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-line therapy for chronic myeloid leukemia: current status and future directions.
    Cortes J; Lang F
    J Hematol Oncol; 2021 Mar; 14(1):44. PubMed ID: 33736651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L; Hughes TE; Walsh-Chocolaad TL
    Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.
    Eide CA; Brewer D; Xie T; Schultz AR; Savage SL; Muratcioglu S; Merz N; Press RD; O'Hare T; Jacob T; Vu TQ; Tognon CE; Macey TA; Kuriyan J; Kalodimos CG; Druker BJ
    Cancer Cell; 2024 Sep; 42(9):1486-1488. PubMed ID: 39214096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacology profile and clinical findings of bosutinib hydrate (Bosulif® Tablets)].
    Tahara M; Shibata A; Katsura S
    Nihon Yakurigaku Zasshi; 2016 May; 147(5):311-8. PubMed ID: 27181728
    [No Abstract]   [Full Text] [Related]  

  • 18. New kinase inhibitor approved for CML.
    Traynor K
    Am J Health Syst Pharm; 2012 Nov; 69(21):1846. PubMed ID: 23111662
    [No Abstract]   [Full Text] [Related]  

  • 19. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
    Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
    Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosutinib more effective than imatinib in CML.
    Gourd E
    Lancet Oncol; 2017 Dec; 18(12):e716. PubMed ID: 29129440
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.